Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer [clinicaltrials:NCT00008398]
Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer [clinicaltrials:NCT00008398]
Bio2RDF identifier
NCT00008398
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00008398
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Sargramostim ...... r head and neck
cancer.
brief title [clinicaltrials_vocabulary:brief-title]
Sargramostim in Decreasing Muc ...... erapy for Head and Neck Cancer
collaborator [clinicaltrials_vocabulary:collaborator]
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES:
- ...... d within 1.2-1.4
years.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2001-01-06T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
oral complications
radiation toxicity
recurrent hypopharyngeal cancer
recurrent lip and oral cavity cancer
recurrent metastatic squamous neck cancer with occult primary
recurrent nasopharyngeal cancer
recurrent oropharyngeal cancer
recurrent paranasal sinus and nasal cavity cancer
stage 0 hypopharyngeal cancer
stage 0 laryngeal cancer
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2013-11-18T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00008398
official title [clinicaltrials_vocabulary:official-title]
A Phase III Study to Test the ...... Head and Neck Cancer Patients
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2004-03-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
CDR0000068406
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2000-10-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2013-11-01T00:00:00Z
identifier
clinicaltrials:NCT00008398
title
Sargramostim in Decreasing Muc ...... erapy for Head and Neck Cancer
@en
type
label
Sargramostim in Decreasing Muc ...... r [clinicaltrials:NCT00008398]
@en